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Individuals with metabolic syndrome (MetS; i.e., three of ﬁve of the following risk fac-
tors (RFs): elevated blood pressure, waist circumference, triglycerides, blood glucose, or
reduced HDL) are thought to be prone to serious cardiovascular disease and there is debate
as to whether the disease begins in the peripheral vasculature or centrally. This study
investigates hemodynamics, cardiac function/morphology, and mechanical properties of
the central (heart, carotid artery) or peripheral [total peripheral resistance (TPR), forearm
vascular bed] vasculature in individuals without (1–2 RFs: n= 28), or with (≥3 RFs: n= 46)
MetS. After adjustments for statin and blood pressure medication use, those with MetS
had lower mitral valve E /A ratios (<3 RFs: 1.24± 0.07; ≥3 RFs: 1.01± 0.04; P = 0.025),
and higher TPR index (<3 RFs: 48± 2mmHg/L/min/m2; ≥3 RFs: 53± 2mmHg/L/min/m2;
P = 0.04).Therewere no differences in heart size, carotid arterymeasurements, cardiovagal
baroreﬂex, pulse-wave velocity, stroke volume index, or cardiac output index due to MetS
after adjustments for statin and blood pressuremedication use.The use of statinswas asso-
ciated with increased inertia in the brachial vascular bed, increased HbA1c and decreased
LDL cholesterol.The independent use of anti-hypertensivemedicationwas associatedwith
decreased predicted VO2 max, triglycerides, diastolic blood pressure, interventricular sep-
tum thickness, calculated left ventricle mass, left ventricle posterior wall thickness, and left
ventricle pre-ejection period, but increased carotid stiffness, HDL cholesterol, and heart
rate. These data imply that both a central cardiac effect and a peripheral effect of vascular
resistance are expressed in MetS.These data also indicate that variance in between-group
responses due to pharmacological treatments are important factors to consider in studying
cardiovascular changes in these individuals.
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INTRODUCTION
The metabolic syndrome (MetS) is known to increase the risk
of more serious cardiovascular disease (Ingelsson et al., 2007).
There is considerable interest in understanding the patterns of
where and when the component metabolic risk factors (RFs)
impact the cardiovascular system so that interventions canbemore
effectively targeted. In MetS there are opposing hypotheses as to
where cardiovascular disease becomes initially established with
some investigators suggesting that early vascular disease compli-
cations begin in peripheral vascular beds (Stokes and Granger,
2005; Struijker-Boudier et al., 2007) whereas others suggest a cen-
tral origin (Tsuchikura et al., 2010) such as the heart or major
elastic conduit arteries.
Ingelsson et al. (2007) reported that the probability of devel-
oping left ventricular hypertrophy and carotid artery stenosis was
higher with MetS whereas the probability of developing periph-
eral artery disease was not signiﬁcantly higher than a reference
population. Similarly, in U.K. patients with Type 2 Diabetes, the
presence of MetS was associated with a greater risk of macrovascu-
lar disease (i.e., myocardial infarction or stroke) without a change
in microvascular complications (i.e., retinopathy, vitreous hem-
orrhage, or renal failure; Cull et al., 2007). On the other hand,
Abdul-Ghani et al. (2006) found that MetS in Israeli Type 2 Dia-
betic patients was associated with a higher risk of microvascular
complications (i.e., microalbuminuria, neuropathy, retinopathy,
or leg ulcers). It may be that the pattern of cardiovascular com-
plications is a function of the severity of MetS risk. Subcutaneous
vessels (∼250μm) in people with MetS have been shown to have
greater media thickness and cross-sectional area (Grassi et al.,
2010). These vessels have also been shown to have impaired
acetylcholine-induced relaxation compared to healthy control ves-
sels; however, vascular stiffness was not different between groups
(Grassi et al., 2010). In an animal model (obese Zucker rats), Fris-
bee (2005) observed reduced nitric oxide bioavailability in skeletal
muscle microvasculature. Kraemer-Aguiar et al. (2008) found that
people with MetS had smaller ﬁnger capillaries and lower func-
tional capillary density. These observations describe the potential
for greater peripheral resistance and perhaps microvascular com-
plications in MetS. Similarly, these results suggest that peripheral
vascular beds, such as the forearm, would express altered pulsatile
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vascular mechanics. Importantly, previous investigations typically
investigated either central or peripheral cardiovascular repercus-
sions of MetS but not in the same individuals and not as a function
of risk proﬁle.
Also, the impact of pharmacologic treatments for the risks
associated with MetS, such as hypertension or hypercholes-
terolemia, may impact the magnitude of effect on the vascular
outcome. Further, the duration, type, and intensity of treat-
ment (i.e., to recommended therapeutic targets or not) can also
inﬂuence the measured outcomes. Whereas some studies report
data from medicated patients (Ingelsson et al., 2007; Della-Morte
et al., 2010; Koivistoinen et al., 2010) others use unmedicated
patients (Ferreira et al., 2005; Ghiadoni et al., 2008) and this
may lead to the divergent data regarding vascular health in MetS
patients.
Therefore, the ﬁrst purpose of this investigation was to investi-
gate concurrently themorphologic andmechanical characteristics
of peripheral (i.e., limb) and central (i.e.,heart and central arteries)
cardiovascular tissues in individuals with a range of MetS RFs to
test the hypothesis that vascular complications inmetabolic disor-
ders begin in peripheral vascular beds. Furthermore, medication
status of these participants was considered as a complicating or
confounding factor.
MATERIALS AND METHODS
All experimental procedures were approved by the Ofﬁce of
Research Ethics at the University of Western Ontario. Every par-
ticipant was aware of his/her right to withdraw from the study at
any time.
PARTICIPANT RECRUITMENT AND ETHICS
Participants were recruited from the public if they had at least
one risk factor of MetS according to the National Cholesterol
Education Program’s Adult Treatment Panel III report (ATPIII;
Grundy et al., 2004). Participants were deﬁned as having MetS if
they had three or more of the following RFs. RFs are: (1) waist
circumference of >102 cm for men and >88 cm for women, (2)
triglycerides of ≥150mg/dL or ≥1.7mmol/L, (3) HDL choles-
terol of <40mg/dL or <1.0mmol/L for men and <50mg/dL or
<1.3mmol/L forwomen, (4) bloodpressure of≥130/≥85mmHg,
and (5) fasting glucose of ≥110mg/dL or ≥6.1mmol/L. Blood
pressure and cholesterol were classiﬁed as a risk factor if the
participant was medicated for related disorders. Types of med-
ications used are found in Table 1. Seventy-two participants were
Caucasian and two were of Middle-eastern descent. Participants
were excluded if they failed a screening cardiac stress test, had
Type 1 diabetes, had a history of major cardiovascular disease,
had orthopedic or rheumatologic problems that impeded exer-
cise, and/or started or changed cholesterol drug use within the
previous 3months. Participants arrived in the lab in a fasted state
and had abstained from alcohol and caffeine for at least 12 h.
ANTHROPOMETRICS AND PLASMA HORMONES
Predicted maximal aerobic capacity (VO2 max) was determined
using a step test as described in Petrella et al. (2001). Height,
weight, waist circumference, and supine manual blood pressure
were measured by the same experimenter. Waist circumference
Table 1 | Cholesterol and anti-hypertensive medication profiles of
participants.
n
Cholesterol medication No drug 49
Statin alone 22
Statin with fenoﬁbrates 1
Statin with absorption
inhibitor
3
Anti-hypertensive medication No drug 34
Diuretic 10
ACE-ARB 22
α2-agonist 1
Multiple drugs (calcium
blocker use n=4)
7
ACE-ARB: either angiotensin converting enzyme inhibitors or angiotensin receptor
blockers.
was measured above the iliac crest. Framingham risk score was
determined using the National Cholesterol Education Program
Risk Assessment Tool for Estimating 10-year Risk of Developing
Hard CHD (Myocardial Infarction and Coronary Death; avail-
able at: http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype
=prof#moreinfo). Cholesterols, triglycerides, glucose, Hb1Ac,
C-reactive protein, and insulin were measured commercially
by Gamma-Dynacare Medical Laboratories (London, Canada).
HOMA-IR was calculated by multiplying the plasma glucose
concentration (mmol/L) with the plasma insulin concentration
(pmol/L) and dividing by 155.
SYSTEMIC HEMODYNAMICS
Continuous blood pressure was measured using ﬁnger cuff
plethysmography (Finometer, Finapres Medical Systems, Arn-
heim, Netherlands) and normalized to a manual blood pressure
measurement to ensure accuracy of measurement. Heart rate
was determined from an echocardiogram. Stroke volume was
determined from the echocardiographic measurements using Z -
derived formulas (de Simone et al., 1996) whereby end-diastolic
volume= 4.5× left ventricle end-diastolic diameter2, end-systolic
volume= 3.72× left ventricle end-systolic diameter2, and stroke
volume= end-diastolic volume – end-systolic volume. Cardiac
output was calculated as stroke volume multiplied by heart rate.
Cardiac output and stroke volume were normalized to body sur-
face area. TPR index was calculated as mean arterial pressure
(as determined from the manual blood pressure measurements)
divided by normalized cardiac output.
ULTRASOUND
Ultrasound images of the carotid and brachial arteries were taken
using a Vivid 7 Dimension system (10MHz; GE Healthcare, Baie
d’Urfe, Canada) with post-processing using EchoPAC Dimension
software. Velocity waveforms of the mean blood ﬂow velocity in
each artery (Vivid 7 Dimension; 4.7MHz), were sent through a
spectrum analyzer (Multigon Neurovision Transcranial Doppler
System Model 500M, Multigon Industries Inc., Yonkers, USA),
and then sampled at 1 kHz for online storage (Powerlab LabChart
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7.2). Brachial and carotid resistance were determined using the
formulas: Flow (mL/min)= velocity× (π× radius2)× 60, Resis-
tance=Mean Arterial Pressure/Flow. Brachial ﬂow was normal-
ized to arm volume. Forearm volume was assessed from the cir-
cumference at wrist (c1), circumference at the largest part of the
forearm (c2), and the length between the two segments was mea-
sured such that Volume = (length × c21 + (c1 × c2) + c22 )/(12π).
Carotid strain was calculated as (Systolic Diameter–Diastolic
Diameter)/Diastolic Diameter. Carotid stiffness was calculated
as [ln(Systolic Pressure/Diastolic Pressure]/Strain. Carotid dis-
tensibility was calculated as Strain/(Systolic Pressure—Diastolic
Pressure). Carotid elasticity modulus was calculated as (Systolic
Pressure–Diastolic Pressure)/Strain.
Echocardiography images were obtained using a Vivid i sys-
tem (GE Healthcare, Baie d’Urfe, Canada) with post-processing
using EchoPAC Dimension software. Pulsed wave Doppler across
the mitral valve was assessed and the passive ﬁlling of the ventri-
cle (E wave) and the active ﬁlling (A-wave) were measured. The
mitral valve E/A ratio (mitral valve inﬂow) and E/E ′ index (left
ventricular relaxation) were used as non-invasive markers of left
ventricular diastolic function (Nagueh et al., 2009).
PULSE-WAVE VELOCITY
Pulse-wave velocity (PWV) was determined from the lag time
between the foot of the velocity signal from the carotid artery
to either the foot of the pressure wave at the ﬁnger or the
foot of the pressure wave at the toe (Piezo Electric Pulse Trans-
ducer, AD Instruments, Colorado Springs, USA). The distance
between the carotid artery and the ﬁngertip or the toe was
measured and used to calculate the velocity of the pulse wave
(distance/time).
All analog signals (electrocardiogram, ultrasound waveforms,
bloodpressure, toe-pulse pressure)were sampled at 1000Hz (Pow-
erlab; ADInstruments, Colorado Springs,USA) and recorded with
LabChart 7.2.
FOREARM VASCULAR BED MECHANICS
The mechanical properties of the forearm vascular bed were
quantiﬁed using a lumped Windkessel modeling approach. This
approach, using brachial artery recordings of blood ﬂow (ultra-
sound) and blood pressure (Finometer calculation) waveforms
has been described in detail (Zamir et al., 2007). Brieﬂy, concur-
rent blood pressure and ﬂow velocity waveforms were measured
at the brachial artery. The harmonics of the pressure waveform
are modiﬁed using variables of compliance (C), viscoelasticity
(K ), and inertia (L) to generate a reconstructed waveform that
matches the actual measured ﬂow waveform with minimal error.
Forearm vascular bed compliance was normalized to arm volume.
These values of C, K, and L represent features that control the
oscillatory component of pulsatile blood ﬂow. Forearm vascular
resistance (R) is also calculated as a steady-state value over the
average cardiac cycle.
BARORECEPTOR SENSITIVITY
At least 5min of data including RR-interval and blood pressure
were determined for a period of supine rest. These data were then
entered into a MATLAB program to determine the cardiovagal
baroreceptor sensitivity using the sequence method (Blaber et al.,
1995; Parlow et al., 1995).
STATISTICAL ANALYSIS
There are two levels of analysis. First, the effect of risk
factor accumulation was assessed by comparing data between
participants with <3 RFs of MetS and participants with ≥3 RFs
of MetS using linear regression adjusted for cholesterol and blood
pressure medications (SAS 9.2, SAS Institute Inc., Cary, USA; see
Table 2). Second, the effects of anti-hypertensive medications or
anti-cholesterol (statin)medications on the central and peripheral
indices of cardiovascular status were also analyzed using linear
regression adjusted for the alternate medication and risk factor
group. Of the various outcomes assessed, those variables that
exhibited a signiﬁcant (or near signiﬁcant) effect of medication are
presented in Tables 3 and 4. Data are presented as means± SD. P-
values of <0.05 were considered statistically signiﬁcant. SE values
are provided in the Figure legends.
RESULTS
EFFECT OF MetS RISK FACTOR PROFILE
The differences between risk factor groups after statistical adjust-
ment for the use of the anti-hypertensive and statin medications
are found in Table 2 and 3 as well as Figures 1–4. In compar-
ison to participants with <3 RFs, participants with overt MetS
were the same age (P = 0.98), but had higher body mass index
(BMI; P = 0.01), lower HDL cholesterol (P < 0.0001), higher
triglycerides (P = 0.002), higher HbA1c (P = 0.02), higher insulin
(P = 0.003), and higher HOMA-IR (P = 0.004). There was a ten-
dency for lower diastolic blood pressure in the MetS group versus
the group with <3 RFs (P = 0.07; Table 2). However, the mean
levels are very close and, for this reason, we attach no physiologic
signiﬁcance to this outcome.
Compared to individuals with <3 RFs, participants with MetS
had similar calculated left ventricle mass (P = 0.49; Figure 1A),
interventricular septal wall thickness (P = 0.12; Figure 1B), and
left ventricular posterior wall thickness (P = 0.17; Figure 1C).
The E/E ′ ratio was not different between groups (P = 0.701;
data not shown). Participants with MetS had a lower mitral
valve E/A ratio (MV E/A ratio) compared to the low risk group
(P = 0.03; Effect Size= 0.7; β= 0.89; Figure 2A), but no differ-
ence in left ventricular pre-ejection period (LVPEP; P = 0.27;
Figure 2B). Also, these groups were not different in carotid artery
strain (P = 0.34; Figure 3A), stiffness (P = 0.40; Figure 3B), dis-
tensibility (P = 0.75; Figure 3C), elasticity modulus (P = 0.23;
Figure 3D), cardiovagal baroreceptor sensitivity (<3 RFs:
12.6± 6.3ms/mmHg; ≥3 RFs: 9.0± 4.7ms/mmHg; P = 0.29),
carotid intima-media thickness (<3 RFs: 0.62± 0.14mm; ≥3
RFs: 0.69± 0.18mm; P = 0.13), stroke volume index (P = 0.19;
Figure 4A), or cardiac output index (P = 0.34; Figure 4B).
Compared to those with <3 RFs, participants with MetS
had higher TPR index (P = 0.04; Effect Size= 0.44; β= 0.55;
Figure 4C).
There were no signiﬁcant differences between groups for fore-
arm vascular resistance (P = 0.41), compliance (P = 0.15), vis-
coelasticity (P = 0.37), or inertia (P = 0.99; Table 3). Similarly,
there was no group effect for carotid vascular resistance (<3
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Table 2 | Anthropometrics, risk factors of metabolic syndrome, and plasma hormones of participants.
<3 risk factors ≥3 risk factors Unadjusted
P -values
P -values
adjusted
for statins
P -values
adjusted for
anti-hypertension
medication
P -values
adjusted for
both statins and
anti-hypertension
medication
n 29 45 – – – –
Number of RFs 1.7±0.5 3.6±0.8* <0.0001 <0.0001 <0.0001 <0.0001
Number of women (%) 58.6 71.1 – – – –
Age 57.7±8.6 59.0±7.0 0.41 0.81 0.68 0.98
Predicted VO2 max (mL/kg/min) 32.5±5.0 29.1±6.1 0.02 0.03 0.17 0.17
Framingham risk score (%) 4.5±4.2 6.1±5.1 0.16 0.37 0.13 0.26
BMI (kg/m2) 30.9±4.0 34.6±5.4* 0.002 0.009 0.005 0.01
Waist circumference (cm) 106.4±11.2 112.0±11.5 0.04 0.1 0.1 0.16
LDL cholesterol (mmol/L) 3.0±0.8 2.5±1.0 0.046 0.26 0.25 0.58
HDL cholesterol (mmol/L) 1.4±0.3 1.1±0.2* <0.0001 0.0006 <0.0001 <0.0001
Triglycerides (mmol/L) 1.2±0.5 1.7±0.8* 0.007 0.01 0.001 0.002
Fasting glucose (mmol/L) 5.5±0.4 5.8±1.0 0.18 0.22 0.11 0.15
HbA1c (%) 5.66±0.31 5.92±0.34* <0.0001 0.01 0.005 0.02
Insulin (pmol/L) 67.5±35.0 105.9±42.7* 0.001 0.003 0.001 0.003
HOMA-IR (pmol/L*mmol/L) 2.4±1.3 4.2±2.0* 0.0008 0.004 0.001 0.004
Heart rate (bpm) 64.9±10.5 67.3±3.6 0.32 0.38 0.78 0.85
Systolic pressure (mmHg) 122.9±14.7 126.7±12.6 0.52 0.37 0.34 0.27
Diastolic pressure (mmHg) 74.4±8.5 73.6±8.1 0.29 0.23 0.07 0.07
C-reactive protein (mg/L) 3.6±5.3 3.2±3.3 0.65 0.94 0.41 0.62
Current smoking (#) 1 3 – – – –
Values aremean±SD. HOMA-IR, homeostaticmodel assessment for insulin resistance; *indicates P-value of<0.05, adjusted for both statin use and anti-hypertension
medication use.
Table 3 | Pulsatile mechanical properties of the forearm vascular bed.
<3 RFs ≥3 RFs Unadjusted
P -values
P -values
adjusted
for statins
P -values
adjusted for
anti-hypertension
medication
P -values
adjusted for
both statins and
anti-hypertension
medication
Resistance (mmHg/mL/min) 6.6±4.9 5.5±3.0 0.23 0.50 0.23 0.41
Compliance (mL/mmHg/cm3) 6.60e−6 ±4.11e−6 5.80e−6 ±2.82e−6 0.33 0.20 0.21 0.15
Viscoelasticity (mmHg/mL/min) 0.19±0.12 0.19±0.13 0.91 0.51 0.58 0.37
Inertia (mmHg/mL/min2) 1.40e−5 ±1.79e−5 1.28e−5 ±1.61e−5 0.77 0.75 0.63 0.99
Values are mean±SD.
RFs: 0.49± 0.17mmHg/mL/min; ≥3 RFs: 0.50± 0.12; P = 0.43),
or for PWV to the ﬁngertip (<3 RFs: 1661± 449 cm/s; ≥3
RFs: 1641± 510 cm/s; P = 0.70), or to the toe (<3 RFs:
1312± 323 cm/s; ≥3 RFs: 1417± 322 cm/s; P = 0.23).
EFFECT OF ANTI-HYPERTENSIVE AND ANTI-CHOLESTEROL
MEDICATIONS
The data were re-evaluated to display the signiﬁcant effects of
anti-hypertensivemedication or statin use (Tables 4 and 5, respec-
tively). The followingdata reﬂect those values thatwere statistically
signiﬁcant, or demonstrated strong statistical trends, following
analysis of medication effects.
Participants taking anti-hypertensive medication had lower
predicted aerobic capacity (VO2 max; P = 0.01), higher HDL cho-
lesterol (P = 0.02), lower triglycerides (P = 0.02), higher heart rate
(P = 0.001), lower diastolic pressure (P = 0.03), lower calculated
left ventricular mass (P = 0.02), thinner interventricular septal
wall (P = 0.003), thinner left ventricular posterior wall (P = 0.02),
shorter LVPEP (P = 0.007), and a less distensible carotid artery
(P = 0.02; Table 4).
Participants taking statins tended to be older (P = 0.06)
and have a higher Framingham risk score (P = 0.06), lower
HDL cholesterol (P = 0.07), higher HOMA-IR (P = 0.07), and
lower forearm vascular resistance (P = 0.09). Participants taking
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Table 4 | Effects of anti-hypertension medication.
No anti-
hypertension
medication
Anti-
hypertension
medication
P -values
Predicted VO2 max
(mL/kg/min)
33±6 28±6 0.01
HDL Cholesterol
(mmol/L)
1.17±0.34 1.19±0.28 0.02
Triglycerides (mmol/L) 1.6±0.7 1.4±0.7 0.02
Heart rate (bpm) 62±7.6 70±10 0.001
Diastolic pressure
(mmHg)
74±8 74±9 0.03
Calculated left
ventricular mass (g)
167±33 149±40 0.02
Interventricular septal
wall thickness (cm)
0.98±0.07 0.93±0.11 0.003
Left ventricular
posterior wall
thickness (cm)
0.95±0.08 0.92±0.09 0.02
Left ventricle
pre-ejection period (ms)
73±15 64±12 0.007
Carotid stiffness (cm) 7.7±4.1 9.5±3.5 0.09
Carotid distensibility
(cm*mmHg−1)
0.0016±0.0007 0.0012±0.0004 0.02
Values are mean±SD.
statins had lower LDL cholesterol (P = 0.002), higher HbA1c
(P = 0.01), and lower brachial artery inertia (L; P = 0.03;
Table 5).
DISCUSSION
The current data suggest that the primary markers of cardiovas-
cular dysfunction in MetS were centrally located in the heart. In
particular, the lower E/A ratio of∼1.0 suggests moderate diastolic
dysfunction in those participants with MetS. The only indicator
of altered peripheral vascular change with MetS was higher TPR,
but with limited statistical power. However, forearm and carotid
vascular resistance were not different between groups suggesting
that visceral abdominal beds might be implicated in the higher
TPR observed with MetS. There was no evidence that forearm
or systemic PWV, carotid, or brachial conduit vessel stiffness, or
the mechanics of the forearm vascular bed were affected by the
degree of risk proﬁle in the two groups. Therefore, vascular stiff-
ness of the central and limb vascular beds was not affected by the
MetS risk proﬁle. Importantly, however, some vascular features
normally attributed to MetS, such as carotid artery stiffness, were
related to the presence of anti-hypertensive or statin medication.
Whether the type, duration or intensity of therapy inﬂuenced the
results is beyond the scope of this paper. Nevertheless, the pres-
ence of medication appears to be an important determinant of
the vascular impact of MetS. Hence, these data suggest that MetS
may be associated with central changes in the left ventricle and
a modest increase in resistance of some non-limb segments of
the vasculature. In contrast, some changes that have been previ-
ously attributed toMetS were more strongly related to medication
FIGURE 1 | Indices of heart size in individuals with metabolic syndrome
(MetS). After adjustment for statin and blood pressure medication use,
compared with individuals with less than three risk factors for cardiovscular
disease (<3 RFs) participants with MetS displayed no differences in (A) left
ventricle mass (P =0.49), (B) interventricular septal wall thickness
(P =0.12), or (C) left ventricular posterior wall thickness (P =0.17). There
were signiﬁcant effects of anti-hypertension medication use and statin use
in all variables (seeTables 4 and 5). Values are mean±SD. Corresponding
SE values are (A) 6.0 g (<3 RFs) and 6.3 g (MetS); (B) 0.02 cm (<3 RFs) and
0.01 cm (MetS); (C) 0.02 cm (<3 RFs) and 0.01 cm (MetS).
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FIGURE 2 | Echocardiography of individuals with metabolic syndrome
(MetS). After adjustment for statin and blood pressure medication use,
compared with individuals with less than three risk factors for cardiovscular
disease (<3 RFs) participants with MetS displayed (A) lower mitral valve
E /A ratio (MV E /A ratio; an indicator of left ventricle relaxation; P =0.03) and
(B) no difference in left ventricular pre-ejection period (LVPEP; P =0.27).
There were signiﬁcant effects of anti-hypertension medication use on
LVPEP (seeTable 4). Values are mean±SD. Corresponding SE values are
(A) 0.07 (<3 RFs) and 0.04 (MetS); (B) 2.0ms (<3 RFs) and 2.6ms (MetS).
use in the current analysis. Thus, it appears that the trajectory of
cardiovascular dysregulation in MetS begins in the heart and not
in limb vascular beds.
By deﬁnition, people with MetS exhibit at least three of the fol-
lowing RFs: elevated blood pressure, waist circumference, triglyc-
erides, blood glucose, or reduced HDL cholesterol (Grundy et al.,
2004). Higher insulin and HOMA values are also observed in
MetS (Vonbank et al., 2011). After adjusting for anti-hypertensive
medication and statin use signiﬁcantly higher BMI, lower HDL
cholesterol, higher triglycerides, and higher HbA1c (an indica-
tor of long-term plasma glucose) were observed in the MetS
group with >3 RFs in this study. The differences in HDL cho-
lesterol and triglycerides reinforce the group classiﬁcation of these
individuals.
Whereas correcting for anti-hypertensive or statin medications
exposed important risk factor proﬁles in our groups, this approach
also highlighted the observation of relatively few cardiovascular
consequences of increasing risk of MetS. Nonetheless, one out-
come that was not altered by the correction for medications was
lower mitral valve E/A ratio. This ﬁnding supports earlier reports
(Gong et al., 2009; Turhan et al., 2009; Hwang et al., 2011). The
E/A value of ∼1.0 suggests modest diastolic dysfunction that can
occur in the absence of any detectable change in systolic function
such as ejection fraction or stroke volume. Nonetheless, a lowered
E/A ratio is commonly associated with a greater risk of devel-
oping congestive heart failure (Arnlov et al., 2004) and this has
raised emphasis for early treatment in MetS patients with con-
comitant left ventricular diastolic dysfunction (Dinh et al., 2011).
The lower E/A ratio was affected by a higherA velocity (P = 0.06).
The mitral A-wave velocity reﬂects the LA–LV pressure gradient
during late diastole, which is affected by LV compliance and LA
contractile function. Thus, from a mechanistic perspective, the
higher A velocity could be a result of left atrial enlargement that
has been observed with MetS (Cuspidi et al., 2005).
It is recognized that the determination of left ventricular dias-
tolic dysfunction is best determined with a more comprehensive
analysis approach (Goncalves et al., 2010) in contrast to the singu-
lar measurement of transmitral ﬂow. The E/E ′ values were within
the normal range for all individuals in the current study suggest-
ing that left ventricular relaxation rate was not affected by the risk
factor proﬁle. Overall, the marker of mitral value ﬁlling dynam-
ics suggests the need for a deeper and focused examination of
left ventricular function in MetS as an early marker of cardiac
disease. Ultrasound-based measurements are non-invasive and
appropriate for large scale studies. However, echocardiography-
basedmeasures may actually underestimate the degree of diastolic
dysfunction (Zile et al., 2004).
Previously, it has been reported that carotid artery distensi-
bility was diminished in individuals with MetS (Ferreira et al.,
2005).Whereas the values of carotid artery distensibility observed
here are similar to those reported earlier in non-medicated MetS
patients (Aizawa et al., 2009), there was no difference between
groups following adjustment for medications (Figure 3C). Unfor-
tunately, it is difﬁcult to make direct comparisons with existing
literature on this topic due to variations in the sample under inves-
tigation. For example, Ferreira et al. (2005) investigated a group of
relatively young (36 years old) and unmedicated individuals and
observed increased stiffness of the carotid artery. Della-Morte et al.
(2010) used medicated participants and statistically adjusted for
medication use and still found higher carotid stiffness in partici-
pants withMetS. However, the participants in theDella-Mort et al.
studywere approximately 6 years older thanourswith amajority of
the participants being of Hispanic or Black race/ethnicity (∼80%).
This is important because middle-aged Black men demonstrate
greater carotid stiffness than caucasian men (Din-Dzietham et al.,
2004). Furthermore, Karlamangla et al. (2010) found that US-
born Black and Hispanic men have a higher metabolic risk in
comparison to a White population. These ﬁndings suggest that
age, ethnicity, and pharmacological treatment are important fac-
tors to consider when evaluating the association between altered
vascular behavior and MetS.
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FIGURE 3 | Carotid artery dynamics of individuals with metabolic
syndrome (MetS). After adjustment for statin and blood pressure medication
use, compared with individuals with less than three risk factors for
cardiovascular disease (<3 RFs) participants with MetS were not different in
carotid artery (A) strain (P =0.34), (B) stiffness (P =0.40), (C) distensibility
(P =0.75), and (D) elastic modulus (P =0.23). There was a trend for an effect
of anti-hypertension medication on carotid stiffness (seeTable 4). There was a
signiﬁcant effect of anti-hypertension medication use on carotid distensibility
(seeTable 4). Values are mean±SD. Corresponding SE values are (A)
0.005 cm−1 (<3 RFs) and 0.004 cm−1 (MetS); (B) 0.6 cm (<3 RFs) and 0.07 cm
(MetS); (C) 0.0001 cm*mmHg−1 (<3 RFs) and 0.0001 cm*mmHg−1 (MetS);
(D) 57 cm*mmHg (<3 RFs) and 67 cm*mmHg (MetS).
It is not clear how anti-hypertensive medications are affecting
the carotid artery. In the current study the unexpected ﬁnding
was that anti-hypertensive treatment was associated with lowered
carotid artery distensibility. While this observation appears para-
doxical it may reﬂect the fact that patients on anti-hypertensive
agents have hypertension, although they were pharmacologically
controlled in this sample.
Nodifferenceswere observed in PWV in participantswithMetS
compared to those with fewer RFs. These observations are in con-
trast to other reports that have found higher PWV in the large
arteries of participants with MetS (Li et al., 2005; Nakanishi et al.,
2005; Kim, 2006; Miyaki et al., 2006; Ghiadoni et al., 2008; Lin
et al., 2009). Two of these earlier investigations recruited partic-
ipants that were not medicated for hypertension or dyslipidemia
(Kim, 2006; Ghiadoni et al., 2008) whereas four other investiga-
tions recruited participants taking medications, but did not adjust
for them (Li et al., 2005; Nakanishi et al., 2005; Miyaki et al.,
2006; Lin et al., 2009). Controlling for hypertensive medications
is important as Ghiadoni et al. (2008) observed that higher blood
pressure was the only risk factor of MetS that is associated with
higher PWV. Further, elevated blood pressure will independently
reduce vascular distensibility by moving the vascular segment to a
stiffer portion of the volume–pressure relationship.
In the current study higher TPR was observed in participants
with MetS compared to those with fewer RFs. The mechanisms of
heightened vascular contractile state in MetS may be related to a
dysfunctional contractile state, such as that induced by abnormal
nitric oxide production (Song et al., 2006) and/or to a remodeled
vascular system with smaller lumen. However, the lack of changes
in vascular stiffness would argue against a remodeled vascular bed.
The site of the observed increased vascular tone is not known. Our
observations suggest that the higher TPR in MetS was not due to
changes in the brachial vascular bed or the carotid system. There-
fore, other vascular beds could play a role. To our knowledge, there
are no data examining the effect of MetS or associated pharmacol-
ogy on the contractile behavior of abdominal vascular beds which
can exert a large inﬂuence on total vascular resistance. Nonethe-
less, the effect was modest with limited statistical power and must
be interpreted cautiously.
The mechanism underlying elevated TPR in MetS could also
reﬂect a reﬂexive sympathetic neural effect as a consequence of
reduced cardiac output. Koivistoinen et al. (2010) found thatMetS
in people aged 30–45 was associated with a higher systemic vascu-
lar resistance index but also a lower stroke volume index. However,
no change in stroke volume or cardiac output index was observed
in the current study. Our adjustment for anti-hypertensive or
statin medications could account for the discrepancy between our
study and the report of Koivistoinen et al. (2010). For example, in
unmedicated participants with MetS, Mule et al. (2007) observed
no difference in stroke volume index. It is acknowledged, however,
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FIGURE 4 | Hemodynamics of individuals with metabolic syndrome
(MetS). After adjustment for statin and anti-hypertensive medication use,
compared with individuals with less than three risk factors for
cardiovascular disease (<3 RFs) participants with MetS displayed (A) no
difference in stroke volume index (P =0.19); (B) no difference in cardiac
output index (P =0.34); and (C) higher total peripheral resistance index
(P =0.04). There were no signiﬁcant effects of anti-hypertension
medication use or statin use for all variables. Values are mean±SD.
Corresponding SE values are (A) 0.9mL/m2 (<3 RFs) and 1.1mL/m2 (MetS);
(B) 0.06 L/min/m2 (<3 RFs) and 0.07 L/min/m2 (MetS); (C)
1.8mmHg/L/min/m2 (<3 RFs) and 2.0mmHg/L/min/m2 (MetS).
that our observations of higher TPR in the MetS group were small
and not accounted for clearly by either a reduced cardiac output
Table 5 | Effects of cholesterol medication (statins).
No statin
adjustment
Statin
adjustment
P -values
Age 57±8 61±4 0.06
Framingham risk
score (%)
4.6±4.2 7.2±5.5 0.06
LDL cholesterol
(mmol/L)
3.0±0.9 2.1±0.7 0.002
HDL cholesterol
(mmol/L)
1.3±0.3 1.1±0.2 0.07
HbA1c (%) 5.7±3.0 6.0±3.7 0.01
HOMA-IR
(pmol/L*mmol/L)
3.0±2.2 4.5±1.7 0.07
Calculated left
ventricular mass (g)
153±35 166±43 0.07
R (mmHg/mL/min) 6.5±4.3 4.7±2.1 0.09
L (mmHg/mL/min2) 1.6e−5 ±1.8e−5 7.7e−6 ±1.2e−5 0.03
Values are mean±SD. HOMA-IR, homeostatic model assessment for insulin
resistance; R and L are resistance and inertia, respectively, from the lumped
Windkessel model.
or elevated blood pressure but smaller contributions of both vari-
ables. Therefore, it is unclear whether vascular remodeling is the
sole source of heightened TPR in this group.
Metabolic syndrome has deleterious effects on the autonomic
nervous system. In particular, baroreﬂex control of heart rate is
diminished. For example, Lindgren et al. (2006) found reduced
cardiovagal baroreceptor sensitivity in unmedicated 70 year old
participants with MetS compared to age-matched controls with
zero RFs for MetS. Much of this reduction in cardiovagal barore-
ﬂex sensitivity may be related to body mass and/or composi-
tion, as reported by Beske et al. (2002) who, using a method of
analysis that is analogous to the spontaneous slope assessment
in this study, reported values of BRS in obese individuals that
match those reported here for MetS participants with <3 RFs.
All participants in the current study had a BMI greater than 30
units and are, thus, considered to be at least overweight if not
obese. Thus, it is expected that all BRS values would be lower
than control groups of the two studies reported above. To our
knowledge, no other studies have examined BRS values within
the range of RFs associated with MetS. Thus, while our data did
not reach statistical signiﬁcance, the cardiovagal baroreﬂex sensi-
tivity in participants with <3 RFs appeared to be higher than in
participants with MetS (<3 RFs: 12.6± 6.3ms/mmHg; ≥3 RFs:
9.0± 4.7ms/mmHg; P = 0.29) and this difference likely reﬂects
the additional effect of other RFs.
EFFECTS OF ANTI-HYPERTENSION MEDICATION
It has been established that blood pressure medication low-
ers and stabilizes blood pressure in hypertensive individuals
by reducing peripheral vasoconstriction or by increasing water
extravasation from the plasma. Therefore, it is not surpris-
ing that we observed lower diastolic pressure in individuals
taking anti-hypertensive medication. We also observed effects
of anti-hypertension medication on predicted aerobic capacity
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(VO2 max), heart rate, HDL cholesterol, triglycerides, left ventricle
size indices, pre-ejection period, and carotid distensibility.
Most evidence points to a beneﬁcial effect of anti-hypertension
medication on exercise capacity (Abdulla et al., 2004; Akbulut
et al., 2006). Therefore, the lower VO2 max in the participants tak-
ing blood pressure medication likely indicates a lower ﬁtness level
in these participants, perhaps due to a more sedentary lifestyle.
This is also evident from the signiﬁcantly higher resting heart rate
observed in the medicated participants.
Associated with the use of anti-hypertension medication, we
observed higher HDL, lower triglycerides, smaller left ventricle
mass index, thinner left ventricle posteriorwalls, and thinner inter-
ventricular septal walls. These results match those of Su et al.
(2000). The use of anti-hypertensive agents could result in the
reversal of left ventricular hypertrophy by lowering of blood pres-
sure and, thereby, afterload. The observed smaller left ventricle and
reduced cardiac afterload in the present study could be responsible
for the shorter left ventricle pre-ejection period that we andDodek
et al. (1975) found with blood pressure medication use. Further-
more, Hamada et al. (1990) found a positive correlation between
left ventricle mass and pre-ejection period in participants with
hypertension.
Spoelstra-de Man et al. (2006) also found lower left ven-
tricular mass after anti-hypertensive drug treatment; however,
at the same time they observed greater distensibility of the
carotid artery which is contrary to our ﬁndings. It is possible
that these inter-study differences are due to the cross-sectional
nature of the current study versus the repeated measures design
of their study which examined experimentally the effect of
anti-hypertensive medication (i.e., the treatment of previously
untreated participants).
EFFECTS OF ANTI-DYSLIPIDEMIC MEDICATION (STATINS)
Lipid medications, particularly statins, are designed to lower the
amount of cholesterol in the body by inhibiting the function of
HMG-CoA reductase which is known to play a fundamental role
in cholesterol synthesis in the liver, hence the lower levels of LDL in
patients using statins.We observed lower HDL, lower LDL, higher
HbA1c, and higher HOMA-IR with statin use. Statin use has been
shown to lower LDL in women with MetS (Guclu et al., 2004).
However, contrary to our ﬁndings, the same study found that statin
use also resulted in higher HDL, lower HbA1c, and lower HOMA.
Our results also seem to be contradictory to those of Su et al.
(2000) who found that statin use decreased cardiac hypertrophy
(we observed a trend for greater left ventricular mass with statin
use). The participants in our cross-sectional study with groups
composed of both males and females had been medicated for at
least 3months prior to the study whereas Guclu et al. (2004) used
a repeated measures design in the same women before and after
statin use. Su et al. (2000) also used a repeated measures design
and gave statins to previously unmedicated participants (all of
their participants also had previously unmedicated hypertension
and were given anti-hypertensive medication). Similar to a previ-
ous report (Neutel et al., 2007) we also observed that statin use
increased with age in a Canadian population. Thus experimental
design, age, and one’s sex may play signiﬁcant roles in the differ-
ences between studies. The increase in age and decrease in HDL
observed in our study are the likely candidates for the higher Fram-
ingham Risk Score observed with statin use. Petrella et al. (2007)
observed greater statin use in older participants with lower HDL.
We found decreased vascular resistance and inertia down-
stream of the brachial artery with statin use. Peripheral arteries
are important in the control of vascular resistance, and statin use
has been shown to increase endothelial function (as measured by
ﬂow-mediated dilation in the brachial artery) in participants with
coronary artery disease (Jarvisalo et al., 1999) or at risk for Type 2
Diabetes (Economides et al., 2004). This greater endothelial func-
tion could help to explain the lower resistance downstream of the
brachial artery in the current study. Similar to the use of anti-
hypertension medication, changes that we have observed due to
statin use could be due to the underlying disease states. Therefore,
these observations need to be interpreted cautiously.
SIGNIFICANCE AND PERSPECTIVES
The purpose of this study was to investigate the effects of MetS on
a broad range of markers for altered central cardiac versus periph-
eral vascular mechanics. We found both central and peripheral
effects in the form of a lower mitral valve E/A ratio and higher
TPR in participants with more RFs. However, the groups could
not be differentiated based on indices of vascular stiffness.We also
investigated the effects of both anti-hypertension medication and
statin use, both of which are common in older populations. The
outcomes of this secondary analysis indicate that some changes
which are typically attributed to MetS were strongly associated
with the presence of anti-hypertensive (such as lower carotid dis-
tensibility or higher PWV) or statin (such as higher HbA1c and
HOMA-IR) medications. Thus, the current ﬁndings suggest that
cardiovascular changes due to MetS do not follow a periphery-
to-central vascular trajectory. In contrast, this study reafﬁrmed
the need to consider diastolic dysfunction as an early marker of
cardiovascular decline in MetS patients.
LIMITATIONS
This study was a cross-sectional design with investigations in indi-
viduals with MetS of varying duration and degree. Follow-up
studies would be required to determine the further progression
of the current observations.
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